AIDS:资源受限环境下HIV成人患者接受二线治疗一年后生活质量得到大大改善

2019-04-03 不详 网络

本研究中,我们评估了成人男性和女性在资源有限的环境(RLS)中使用二线抗逆转录病毒疗法(ART)1年后的生活质量(QoL)的改善,比较了两个随机治疗组。艾滋病临床试验组A5273是一项二线抗病毒治疗的随机临床试验,在9个RLS中的15个地点比较了非核苷酸逆转录酶抑制剂(NNRTIs)治疗失败的患者中洛匹那韦/利托那韦(LPV/r)+雷特格韦与LPV/r +核苷酸逆转录酶抑制剂(NRTIs)的治疗效

本研究中,我们评估了成人男性和女性在资源有限的环境(RLS)中使用二线抗逆转录病毒疗法(ART)1年后的生活质量(QoL)的改善,比较了两个随机治疗组。

艾滋病临床试验组A5273是一项二线抗病毒治疗的随机临床试验,在9个RLS中的15个地点比较了非核苷酸逆转录酶抑制剂(NNRTIs)治疗失败的患者中洛匹那韦/利托那韦(LPV/r)+雷特格韦与LPV/r +核苷酸逆转录酶抑制剂(NRTIs)的治疗效果。参与者完成了艾滋病临床试验组简表21,包括8个QoL域,标准分为0(最差)至100(最佳)。通过随机化臂以及人口统计学和临床变量的QoL差异通过基线回归模型和使用广义估计方程法拟合的48周QoL得分来评估。

结果共纳入512名患者(49%男性,中位年龄39岁)。共有512名和492名参与者分别在基线和第48周进行了QoL评估。从基线到第48周QoL明显改善(所有域P <0.001)。治疗组之间各域没有显著差异。基线时具有较高病毒载量和较低CD4细胞计数的患者在基线时具有较低的平均QoL,但在第48周时得到较大的改善,平均QoL相似。

总之,该研究结果表明,在RLS中,开始LPV/r联合雷特格韦的二线ART与联合NRTI的ART,QoL的改善是相似的。在开始二线治疗之前,疾病状态较差的参与者的基线QoL评分较低,但在1年后,获得了相似的QoL评分。

原始出处:

Torres TS, Harrison LJ, et al., Quality of life improvement in resource-limited settings after one year of second-lineantiretroviral therapy use among adult men and women. AIDS. 2018 Mar 13;32(5):583-593. doi: 10.1097/QAD.0000000000001738.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2033874, encodeId=5a2520338e4ef, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Oct 16 06:04:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365642, encodeId=de5113656421c, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Fri Apr 05 05:04:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543931, encodeId=c0d51543931ba, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24022, encryptionId=02982402298, topicName=二线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520213623738, createdName=ms5768352621950538, createdTime=Fri Apr 05 05:04:00 CST 2019, time=2019-04-05, status=1, ipAttribution=)]
    2019-10-16 wjywjy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2033874, encodeId=5a2520338e4ef, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Oct 16 06:04:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365642, encodeId=de5113656421c, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Fri Apr 05 05:04:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543931, encodeId=c0d51543931ba, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24022, encryptionId=02982402298, topicName=二线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520213623738, createdName=ms5768352621950538, createdTime=Fri Apr 05 05:04:00 CST 2019, time=2019-04-05, status=1, ipAttribution=)]
    2019-04-05 cooco
  3. [GetPortalCommentsPageByObjectIdResponse(id=2033874, encodeId=5a2520338e4ef, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1072181, createdName=wjywjy, createdTime=Wed Oct 16 06:04:00 CST 2019, time=2019-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365642, encodeId=de5113656421c, content=<a href='/topic/show?id=41fa21e036' target=_blank style='color:#2F92EE;'>#AIDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2170, encryptionId=41fa21e036, topicName=AIDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbcc223, createdName=cooco, createdTime=Fri Apr 05 05:04:00 CST 2019, time=2019-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543931, encodeId=c0d51543931ba, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24022, encryptionId=02982402298, topicName=二线治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520213623738, createdName=ms5768352621950538, createdTime=Fri Apr 05 05:04:00 CST 2019, time=2019-04-05, status=1, ipAttribution=)]